Concepedia

Author

Morrison Jusu

University of Sierra Leone

Also Known As

M Jusu, M O Jusu, Melvin Johnson, Morrison Jusu, Morrison O Jusu, T Hilton

7

Publications

415

Citations

7

H-Index

8

Concepts

All Affiliations

University of Sierra LeoneMwanza Intervention Trials UnitJanssen (Belgium)National Institute for Medical ResearchLondon School of Hygiene & Tropical Medicine
MJ

About

Morrison Jusu is an author at University of Sierra Leone specializing in vaccination, epidemiology, and vaccine safety.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

3

263

2

Epidemiology

2

3

263

3

Emerging Infectious Diseases

2

3

263

4

Infection Control

2

3

263

5

Vaccine Development

1

1

85

Morrison Jusu

×

4

Publications

225

Citations

4

H-Index

YearCitations

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

Muhammed O. Afolabi, David Ishola, Daniela Manno,

The Lancet Infectious Diseases

2021

89

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

David Ishola, Daniela Manno, Muhammed O. Afolabi,

The Lancet Infectious Diseases

2021

85

Rapid Establishment of a Cold Chain Capacity of –60°C or Colder for the STRIVE Ebola Vaccine Trial During the Ebola Outbreak in Sierra Leone

Morrison Jusu, Geoffrey Glauser, Jane F. Seward,

The Journal of Infectious Diseases

2017

39

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in infants: a phase 2, randomised, double-blind, active-controlled trial in Guinea and Sierra Leone

E Choi, Boris Lacarra, Muhammed O. Afolabi,

The Lancet Global Health

2023

12

Page 1